11,652 Shares in Moderna, Inc. $MRNA Bought by Saxon Interests Inc.

Saxon Interests Inc. purchased a new position in Moderna, Inc. (NASDAQ:MRNA) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 11,652 shares of the company’s stock, valued at approximately $344,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. New Mexico Educational Retirement Board lifted its holdings in Moderna by 1.9% in the 4th quarter. New Mexico Educational Retirement Board now owns 15,700 shares of the company’s stock valued at $463,000 after purchasing an additional 300 shares in the last quarter. Cromwell Holdings LLC lifted its holdings in Moderna by 39.7% in the 4th quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock valued at $35,000 after purchasing an additional 341 shares in the last quarter. IFP Advisors Inc lifted its holdings in Moderna by 5.4% in the 4th quarter. IFP Advisors Inc now owns 6,785 shares of the company’s stock valued at $200,000 after purchasing an additional 348 shares in the last quarter. Empowered Funds LLC lifted its holdings in Moderna by 2.6% in the 4th quarter. Empowered Funds LLC now owns 13,732 shares of the company’s stock valued at $405,000 after purchasing an additional 353 shares in the last quarter. Finally, Deseret Mutual Benefit Administrators lifted its holdings in Moderna by 16.9% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 2,640 shares of the company’s stock valued at $78,000 after purchasing an additional 382 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Stock Up 0.5%

Shares of NASDAQ:MRNA opened at $49.91 on Friday. The company has a quick ratio of 2.35, a current ratio of 2.41 and a debt-to-equity ratio of 0.08. Moderna, Inc. has a 52-week low of $22.28 and a 52-week high of $59.55. The company has a 50 day moving average of $49.61 and a two-hundred day moving average of $44.03. The company has a market capitalization of $19.80 billion, a price-to-earnings ratio of -6.12 and a beta of 1.05.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Friday, May 1st. The company reported ($3.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.02) by ($0.38). Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The firm had revenue of $389.00 million during the quarter, compared to analyst estimates of $236.37 million. During the same period last year, the business earned ($2.52) EPS. The firm’s revenue was up 260.2% compared to the same quarter last year. As a group, analysts forecast that Moderna, Inc. will post -6.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on MRNA. Evercore set a $35.00 target price on shares of Moderna in a report on Tuesday, February 17th. The Goldman Sachs Group increased their price objective on shares of Moderna from $43.00 to $49.00 and gave the stock a “neutral” rating in a report on Friday, May 1st. Royal Bank Of Canada increased their price objective on shares of Moderna from $35.00 to $38.00 and gave the stock a “sector perform” rating in a report on Monday, May 4th. Barclays increased their price objective on shares of Moderna from $25.00 to $48.00 and gave the stock an “equal weight” rating in a report on Thursday, April 2nd. Finally, UBS Group reiterated a “neutral” rating on shares of Moderna in a report on Tuesday, May 26th. Two research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and five have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Moderna currently has a consensus rating of “Reduce” and a consensus target price of $36.60.

Insider Activity at Moderna

In related news, Director Noubar Afeyan sold 9,263 shares of the firm’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $46.84, for a total value of $433,878.92. Following the sale, the director directly owned 3,924 shares in the company, valued at $183,800.16. This trade represents a 70.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, President Stephen Hoge sold 53,336 shares of the company’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $48.40, for a total transaction of $2,581,462.40. Following the completion of the sale, the president directly owned 1,477,997 shares of the company’s stock, valued at $71,535,054.80. The trade was a 3.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 71,752 shares of company stock valued at $3,453,843. Insiders own 10.80% of the company’s stock.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.